chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Rash; Lymph nodes are swollen; Chills; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Lymph nodes are swollen), RASH (Rash) and CHILLS (Chills) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20-2A) for COVID-19 vaccination.     Concurrent medical conditions included Celiac disease and Graves' disease. Concomitant products included ETHINYLESTRADIOL, NORGESTREL (CONTRACEPTIVE HD) for an unknown indication.    On 06-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced LYMPHADENOPATHY (Lymph nodes are swollen), RASH (Rash) and CHILLS (Chills). At the time of the report, LYMPHADENOPATHY (Lymph nodes are swollen), RASH (Rash) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details were not reported by the reporter.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Patient developed fever evening after vaccines were administered (6/14/07). By 6/15/07 fever was nearly 104 deg F. Patient taken to local emergency room.
Swelling in arm from shoulder to wrist.  Appeared 5 days after shot. Arm achy
Stroke; bleed in the head; headaches; acting like she was on drugs; This is a spontaneous report from a contactable consumer. A 62-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Batch/Lot number: ER8733) via unspecified route of administration on 06Apr2021 as single dose for COVID-19 immunization. Medical history and concomitant medication were not reported. Patient had previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection; Batch/Lot number: EN6208) via unspecified route of administration on 15Mar2021 as single dose for COVID-19 immunization. Patient did not receive other vaccine in four weeks of vaccination. No event following prior vaccinations. In Jun2021 (after 2 months of vaccination), patient had stroke. On an unspecified date in 2021, patient had bleed in the head, headaches and she was acting like she was on drugs. Events require a visit to emergency room. Stroke occurred in Jun2021 after the second dose. She went to the hospital and they could not find anything wrong with her. Other than she was acting like she was on drugs and she does not take drugs or drink. She does not take medications and was a go getter. Patient was not admitted in the hospital and was taken home and now dealing with headaches, which are ongoing and persisting. When she had stoke or whatever she had, could not remember where she was or anybody but could hear everybody. Reporter seriousness for had stroke, bleed in the head and headaches was unspecified. Outcome for stroke and headaches was not resolved and for other events was unknown.
patient was given Pfizer vaccine that was for 12 and older , rather then Pfizer for 5-11 yrs.
I am 54 years old and have not had a period in the last 6 years I just started my period 2 days ago. My whole body has felt inflamed since I received the vaccine and now I'm having a period
The patient's mother stated that on Tuesday morning the day after she received her immunizations there was a red area at the injection site. By Tuesday night the red area bigger and hard. On Wednesday morning the spot was still big and hard. It was also warm to the touch.
Vaccine expired on 11/30/2022 and administered on 12/01/2022
Had booster flu shot 9/6/12 on 9/17/12 was dizzy and had a headache for a day and a half.
Patient was diagnosed with Bells Palsy. On 3/15/21, patient noticed loss of taste and a sensation in his tongue. On 3/16/21, patient had right sided facial paralysis with some right ear discomfort, right eyelid drooping, right upper temple headache, sensitivity to sounds, and right eye only able to be open halfway. Patient also states that his right eye was watery. He denies a mouth droop. Patient went to urgent care on 3/16 and he was prescribed Prednisone. On 3/18, patient went to see his primary care physician and was prescribed an antiviral. He has not had any new or worsening symptoms since 3/18 pm, but he has not seen much improvement in symptoms either. He describes a small improvement in taste.
Light-headedness Narrative:  Pt on 15min observation and complained of being lightheaded; BP taken at 1606, BP 120/80; pt was observed for another 15mins; VS taken at 1623, BP 102/62, HR 71, 02Sat 100%; pt states she is feeling better and ready to go home.
swelling of the throat; lump in my throat; heart was beating a bit faster; This spontaneous case was reported by a consumer and describes the occurrence of PHARYNGEAL SWELLING (swelling of the throat), SENSATION OF FOREIGN BODY (lump in my throat) and PALPITATIONS (heart was beating a bit faster) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Lot# 021C21A) for COVID-19 vaccination. Family history included Drug allergy (mom is allergic to the codeine.) since an unknown date. Concomitant products included STRONTIUM and Calcium supplements for an unknown indication. On 05-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PHARYNGEAL SWELLING (swelling of the throat), SENSATION OF FOREIGN BODY (lump in my throat) and PALPITATIONS (heart was beating a bit faster). At the time of the report, PHARYNGEAL SWELLING (swelling of the throat), SENSATION OF FOREIGN BODY (lump in my throat) and PALPITATIONS (heart was beating a bit faster) outcome was unknown. Not Provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. Treatment medication was not provided.
Left deltoid area red, swollen , warm, tender, oozing, central serosang oozing.
Pt reported lightheadedness approx 5-10 minutes after vaccine administration which resolved in approx 30 minutes  Narrative:  Pt reported feeling lightheaded approx 5-10 minutes after vaccine administration. VS obtained with BP 120/86, HR 88, SPO2 95% on RA. Denied other symptoms. Monitored for additional 15 minutes, pt drank water. Lightheadedness resolved and pt felt back to baseline after approx 30 minutes and  returned home with precautions to return to ED for new or worsening symptoms.
In my left ear I had Tinnitus and lost of hearing it was pretty significant loss of hearing and the doctor did a Tympanic injection with steroids. I had those symptoms for about 3 days before going to the doctor and today I have gotten better but still have reduced hearing. I have another doctors appointment on 9/30/22.
Patient was given a dose of the 6mo-4 year vaccine instead of a dose of the 12+ vaccine.
After 2 weeks arm is still sore and having difficulty lifting anything over 5lbs with the left arm.
HIGH FEVER, VOMITING, CHILLS, SHAKES, SICK IN BED, STARTED THE EVENING AFTER THE INJECTION CONTINUING TODAY, PATIENT MISSING WORK WITH SEVERE FLU SYMPTOMS. HE STATES HE HAD CHICKEN POX WHEN HE WAS ABOUT 20 YEARS OLD.
hot to touch; big lump; pain in her arm; swelling; This spontaneous case was reported by a patient and describes the occurrence of INJECTION SITE WARMTH (hot to touch), INJECTION SITE MASS (big lump), INJECTION SITE SWELLING (swelling) and INJECTION SITE PAIN (pain in her arm) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage form. On 09-Jan-2021, the patient experienced INJECTION SITE SWELLING (swelling). On 19-Jan-2021, the patient experienced INJECTION SITE WARMTH (hot to touch), INJECTION SITE MASS (big lump) and INJECTION SITE PAIN (pain in her arm). At the time of the report, INJECTION SITE WARMTH (hot to touch), INJECTION SITE MASS (big lump), INJECTION SITE SWELLING (swelling) and INJECTION SITE PAIN (pain in her arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.
Vaccine administered 6-22-09, 2nd dose of Hepatitis A vacccine. That evening headache, myalgias, chills, low grade fever 99.3. Evening of 6-25-09, headached, myalgias, low grade fever, intense arthralgias, red skin on trunk. Reaction continued to 6-26-09 with intense joint stiffness,pain, generalized skin erythema and flushing. Continued to 6-27-09 with intense neck stiffness, joint effusion on right knee, right ankle, swollen hands, continued generalized skin erythema. Some improvement on 6-28-09. 90% improved on 6-29-09. Hand swelling and joint effusions had gradually improved.
Information has been received from a licensed practical nurse (L.P.N.) concerning a male who on 29-OCT-2010 was intramuscularly vaccinated with a dose of expired PNEUMOVAX 23 (lot # 662842/1296X) in the right arm. Concomitant therapy included influenza virus vaccine (unspecified) in the left arm. Patient had unspecified local site reaction post vaccination. But during followup visit the patient had recovered. The patient sought unspecified medical attention. This is one of several reports received from the same source. No further information is available.
Pt came in Sat 10-8-11 complaining about his right arm. The location where he received his pneumonia shot was very red and warm to the touch. The diameter of the redness was larger than the band-aid all the way around.
40 hours post Pneumococcal vaccine: Temp 101.1, injection site with erythema, mild hives
Information has been received from a pharmacist concerning a patient who was part of a group of "24 reported reactions" out of 200 vaccinated employees and was vaccinated "during the first week of October, 2003" with a dose dose of pneumococcal 23v polysaccharide vaccine. Concomitant therapy "during the first week of October, 2003, included influenza virus vaccine. It was noted that all of them received both vaccines in the same arm at their request.  The patient "had trouble breathing. Other complaints were sore throat, nausea, vomiting, diarrhea and aches all over. It was noted that many spent the entire weekend in bed after being vaccinated on a Friday and some missed work for a few days after that". The pharmacist suggested Ibuprofen or Tylenol for the "symptoms" and to follow up with their physicians. The reporter expressed concern about the particular lot of vaccine and mentioned that the patients were vaccinated "all from Lot 0676M". Unspecified medical treatment was sought. There was no product quality complaint involved. Follow information indicated that the reporter did not have more information to add to the reports as she did not speak directly to any of the 24 patients in this case. The records of testing prior to release of this lot have been checked by QA and found to be satisfactory. The lot complies with the standards of the Center for Biologics Evaluation and Research and was released. The reporter also mentioned two other patient and 21 patient who were parts of the 24 "reported reactions" and were vaccinated with dose of pneumococcal 23v polysaccharide. Additional information has been requested.
Patient was pale after receiving the shot about 5 minutes afterwards. Lips were pale and looked like she was going to fall over. She was given an ice pack, Sprite, and a fan to cool off. Paramedics were called. Upon assessment she had low blood pressure, but breathing and pulse was normal. Her syncope may be due to anxiety and panic after receiving the vaccine. Patient was monitored and slowly returned to normal after 15 minutes. Patient returned home with her mother and was advised to have patient stay in a cool off and slowly introduce food into her stomach once she is beginning to feel better.
Swollen arm pit; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 02Apr2021 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021, on the 2nd day after 1st dose, the patient experienced swollen arm pit that lasted around 5 days. The clinical outcome of the event swollen arm pit was recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
redness on injection site; swelling on injection site; itching on injection site; hardness on injection site; localized reaction; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE ERYTHEMA (redness on injection site), INJECTION SITE SWELLING (swelling on injection site), INJECTION SITE PRURITUS (itching on injection site), INJECTION SITE INDURATION (hardness on injection site) and INJECTION SITE REACTION (localized reaction) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015m20a) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, the patient experienced INJECTION SITE ERYTHEMA (redness on injection site), INJECTION SITE SWELLING (swelling on injection site), INJECTION SITE PRURITUS (itching on injection site), INJECTION SITE INDURATION (hardness on injection site) and INJECTION SITE REACTION (localized reaction). At the time of the report, INJECTION SITE ERYTHEMA (redness on injection site), INJECTION SITE SWELLING (swelling on injection site), INJECTION SITE PRURITUS (itching on injection site), INJECTION SITE INDURATION (hardness on injection site) and INJECTION SITE REACTION (localized reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
PATIENT  NOTIFY TO THE FACILITY ON 04/14/23 WHEN HE CAME TO RECEIVE THE SECOND DOSE OF SHINGRIX. HE SAID THAT AFTER THE FIRST DOSE HE PRESENT A SKIN REACTION SIMILAR TO A CELLULITIS ON THE ADMINISTRATION SITE. HE VISITED A DOCTOR FOR A FOLLOW UP OF OTHER CONDITIONS AND THE DOCTOR ONLY SAID  TO HIM TO OBSERV THAT DO NOT GROW ANY MORE, AFTER THAT, THE REACTION BEGINS TO REDUCE UNTIL DISAPPEAR.
Information has been received from a registered nurse concerning a 5 year old white male who on 29-Aug-2002 and 30-Oct-2006 was vaccinated with his first and second doses of PROQUAD (lot #653355/0301F) in the left deltoid.  On 23-Jul-2007 the patient developed varicella via exposure from his brother characterized by 2 lesions on the abdomen and 1 lesion on the upper leg.  Medical attention was sought and the patient was treated with ZOVIRAX 400mg TID for 5 days.  On 30-Aug-2007 the patient recovered.  The reporter considered the patient's experience to be an other important medical event since medication was prescribed.  This is one of several reports from the same source.  Additional information is not expected. Follow-up information from the reporting registered nurse indicated that the patient received the first dose of varicella virus vaccine live (oka/Merck) not measeles virus vaccine live (enders-Edmonston) (+) mumps virus live (Jeryl Lynn) (+) rubella virus live (Wistar RA 27/3) (+) varicella virus vaccine live (Oka/Merck upgrade process) on 29-Aug-2002.  The patient developed 7 lesions on his abdomen and 1 lesion on his upper leg and the patient's brother (WAES#0789USA63364) was the first brother to experience the lesion on the mid right abdomen.  The reporter stated there was no mention of an exposure to VZV WILD TYPE STRAIN virus in the patient's chart.  The patient recovered.  It was noted that there were no reocurrences of the event.  This is one of several reports from the same source.
After the second dose of the vaccine, I suffered severe depression for 8 months.  I suffered with suicidal ideations and struggled to get through each day.
Patient describes having hives, redness, and large welts on arms, legs, feet and elbows the morning following vaccination and daily since.  He has taken flu vaccine in the past with no event.  He has no primary care provider.  He took Benadryl today at 10:30am. I told him I would report these adverse events to VAERS.
Stiff neck on same side that injection was administered. I was extremely limited in range of motion in all directions. Today is 10/17/14 and I am unable to extend, but side to side is uncomfortable, but able to complete.
STROKE; This spontaneous report received from a patient concerned a 61 year old male. The patient's weight was 175 pounds, and height was 72 inches. The patient's concurrent conditions included: non-alcohol user, smoker, marginal sugar, and marginal blood pressure, and other pre-existing medical conditions included: The patient had no known drug allergies and no history of drug abuse or illicit drug usage. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, batch number and expiry date were not reported) dose was not reported, Vaccinated at Arm (unspecified), 1 total administered on 29-MAY-2021 for covid-19 prophylaxis. Age at time of vaccination 61 years old. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On 18-JUN-2021, 20 days after the vaccine, the patient experienced stroke and after that on an unspecified date, the patient now had paralyzed in the left arm due to the stroke he had due to the vaccine. The patient was very upset regarding what happened and stated that he would never take another vaccine in his life. Since the stroke, patient was on so many medication. He also stated that let the upper board members know that are receiving bonuses that they have expedited his death and he would be dead shortly. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from stroke. This report was serious (Other Medically Important Condition). This report was associated with a product quality complaint: 90000268985.; Sender's Comments: V0: 20230159993-Stroke. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event. Therefore, the Causality is considered indeterminate. The company causality is considered unassessable.
Severe migraine headache lasting approximately 24 hours. Treated with Aleve and gradually subsided.
A report has been received from a Health Professional concerning a 36 year old, Male subject, who had been receiving FLUMIST quadrivalent (intranasal). FLUMIST quadrivalent started on 13-Jan-2015. It was reported that the patient received expired FLUMIST quadrivalent which started on 13-Jan-2015. The outcome of the event of expired FLUMIST is unknown. The report was considered to be non-serious.
This case was reported by a consumer via call center representative and described the occurrence of pain in arm in a 78-year-old male patient who received SHINGRIX for prophylaxis. Co-suspect products included SHINGRIX for prophylaxis. On 4th December 2018, the patient received the 1st dose of SHINGRIX (intramuscular). On 4th April 2019, the patient received the 2nd dose of SHINGRIX. On 4th December 2018, unknown after receiving SHINGRIX and not applicable after receiving SHINGRIX, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. In April 2019, the patient experienced pain in arm and malaise. On an unknown date, the outcome of the pain in arm and malaise were not recovered/not resolved and the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown. It was unknown if the reporter considered the pain in arm and malaise to be related to SHINGRIX. Additional details were provided as follows: The wife of the patient reported that her husband possibly only received the adjuvant because the pharmacist withdrew the medication out of a vial with a red metal collar into the syringe, which led to the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. The wife reported that her husband experienced arm pain and experienced malaise. The wife reported that with her husband's 2nd dose, the vaccine was withdrawn from a vial with a green metal collar into the syringe. The wife reported that her husband planned to follow up with his pharmacy, and physician on an unknown date. This case linked with US2019061877, reported by same reporter.
8-4- visit office 9/5/2023 with rash all over the body mostly on face and central part of body. Per mother, pt developed rash following fever and (illegible) 8/26/2023, did not go to the ER (illegible) 9/1/2023
Developed redness, warmth, firmness and pain at injection site. No fever. Seen in office 3/3/17 with erythema, warm and tender to touch left upper arm. Area improved at time of visit per mom.
Rash, itching, took BENADRYL 50mg followed by 25 mg Q6 hour.
Hotness; Very tired; Headache; This spontaneous case was reported by a consumer and describes the occurrence of FEELING HOT (Hotness), FATIGUE (Very tired) and HEADACHE (Headache) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 009C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Apr-2021, the patient experienced FEELING HOT (Hotness), FATIGUE (Very tired) and HEADACHE (Headache). On 30-Apr-2021, FEELING HOT (Hotness), FATIGUE (Very tired) and HEADACHE (Headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment information was reported.   This case was linked to MOD-2021-101181 (Patient Link).
pt devel immed swelling w/urticaria & redness @ inject site following the MMR vax; no further details were provided;
chills, fever, nasty headache, muscle aches, fatigue     all symptoms went away approximately 36 hours after vaccination